114 related articles for article (PubMed ID: 19961648)
1. Effectiveness of the immunomodulatory extract of Kalanchoe pinnata against murine visceral leishmaniasis.
Gomes DC; Muzitano MF; Costa SS; Rossi-Bergmann B
Parasitology; 2010 Apr; 137(4):613-8. PubMed ID: 19961648
[TBL] [Abstract][Full Text] [Related]
2. Toxicological analysis and effectiveness of oral Kalanchoe pinnata on a human case of cutaneous leishmaniasis.
Torres-Santos EC; Da Silva SA; Costa SS; Santos AP; Almeida AP; Rossi-Bergmann B
Phytother Res; 2003 Aug; 17(7):801-3. PubMed ID: 12916081
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory pretreatment with Kalanchoe pinnata extract and its quercitrin flavonoid effectively protects mice against fatal anaphylactic shock.
Cruz EA; Da-Silva SA; Muzitano MF; Silva PM; Costa SS; Rossi-Bergmann B
Int Immunopharmacol; 2008 Dec; 8(12):1616-21. PubMed ID: 18675940
[TBL] [Abstract][Full Text] [Related]
4. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice.
Gomes DC; Pinto EF; de Melo LD; Lima WP; Larraga V; Lopes UG; Rossi-Bergmann B
Vaccine; 2007 Mar; 25(12):2168-72. PubMed ID: 17240003
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538
[TBL] [Abstract][Full Text] [Related]
6. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
[TBL] [Abstract][Full Text] [Related]
7. Oral metabolism and efficacy of Kalanchoe pinnata flavonoids in a murine model of cutaneous leishmaniasis.
Muzitano MF; Falcão CA; Cruz EA; Bergonzi MC; Bilia AR; Vincieri FF; Rossi-Bergmann B; Costa SS
Planta Med; 2009 Mar; 75(4):307-11. PubMed ID: 19085683
[TBL] [Abstract][Full Text] [Related]
8. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
9. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL
Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
[TBL] [Abstract][Full Text] [Related]
12. Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.
Vilela Mde C; Gomes DC; Marques-da-Silva Ede A; Serafim TD; Afonso LC; Rezende SA
Acta Trop; 2007; 104(2-3):133-9. PubMed ID: 17919443
[TBL] [Abstract][Full Text] [Related]
13. Tinospora cordifolia as a protective and immunomodulatory agent in combination with cisplatin against murine visceral leishmaniasis.
Sachdeva H; Sehgal R; Kaur S
Exp Parasitol; 2014 Feb; 137():53-65. PubMed ID: 24370645
[TBL] [Abstract][Full Text] [Related]
14. The importance of TGF-beta in murine visceral leishmaniasis.
Wilson ME; Young BM; Davidson BL; Mente KA; McGowan SE
J Immunol; 1998 Dec; 161(11):6148-55. PubMed ID: 9834100
[TBL] [Abstract][Full Text] [Related]
15. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
16. Immunohistological features of visceral leishmaniasis in BALB/c mice.
Carrión J; Nieto A; Iborra S; Iniesta V; Soto M; Folgueira C; Abanades DR; Requena JM; Alonso C
Parasite Immunol; 2006 May; 28(5):173-83. PubMed ID: 16629702
[TBL] [Abstract][Full Text] [Related]
17. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
Webb JR; Kaufmann D; Campos-Neto A; Reed SG
J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
[TBL] [Abstract][Full Text] [Related]
18. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
19. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
20. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma.
Murray HW; Stern JJ; Welte K; Rubin BY; Carriero SM; Nathan CF
J Immunol; 1987 Apr; 138(7):2290-7. PubMed ID: 3104456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
